Form 4: TransMedics Group Executive Tamer Khayal Reports Stock and Option Transactions

Chief Commercial Officer Tamer Khayal reports acquisition of restricted stock units and stock options in TransMedics Group, Inc.

Summary

• Tamer Khayal, Chief Commercial Officer of TransMedics Group, Inc. (TMDX), reported transactions involving the company's securities.
• On February 24, 2025, Khayal acquired 17,606 restricted stock units (RSUs), each representing a contingent right to receive one share of TMDX common stock.
• Also on February 24, 2025, Khayal acquired options to purchase 26,499 shares of common stock at an exercise price of $77.12.
• The stock options vest monthly at a rate of 2.0833% starting February 24, 2025, and will be fully vested on February 24, 2029, contingent upon continued service.
• Following these transactions, Khayal directly owns 38,449 shares of TransMedics Group, Inc. common stock and options to purchase 26,499 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and RSUs by a key executive suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of RSUs and stock options by a key executive signals confidence in the company's future performance.
• The vesting schedule of the options incentivizes continued service and commitment from the Chief Commercial Officer.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the executive's compensation structure and investment in the company's equity.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as they demonstrate the executive's alignment with the company's success.

Key Dates